Veradermics Q2 2026 net loss widens to $23.5 million; cash rises to $819.9 million
Veradermics reported a second-quarter 2026 net loss of $23.5 million, up from $15.6 million a year earlier, as research and development and general and administrative costs rose. The company had $819.9 million in cash, cash equivalents and marketable securities on June 30, 2026, after raising about $472.0 million in gross proceeds in May 2026, and it expects that cash to fund operations into 2030.
Key points
- Net loss was $23.5 million for Q2 2026 versus $15.6 million for Q2 2025.
- R&D expenses rose to $18.6 million from $14.3 million; G&A expenses rose to $10.9 million from $1.7 million.
- Cash, cash equivalents and marketable securities were $819.9 million on June 30, 2026, up from $141.9 million on December 31, 2025.
- Topline data from Phase 2/3 Study '306' are expected in the first half of 2027; Study '304' and 12-month Study '302' data are expected in the second half of 2026.
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 11, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.